Table 5 Correlation between RASSF1A protein expression and clinicopathological parameters of ESCC and GCA patients
Classification | ESCC (n=27) | GCA (n=24) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
N | Positive | Negative | P | OR(95%CI) | N | Positive | Negative | P | OR(95%CI) | ||||||||
n | (%) | n | (%) | n | (%) | n | (%) | n | (%) | n | (%) | ||||||
Gender | |||||||||||||||||
Male | 18 | (67) | 10 | (56) | 8 | (44) | 14 | (58) | 6 | (43) | 8 | (57) | |||||
Female | 9 | (33) | 7 | (78) | 2 | (22) | 0.27 | 0.36(0.06–2.22) | 10 | (42) | 8 | (80) | 2 | (20) | 0.08 | 0.19(0.03–1.23) | |
Age(y) | |||||||||||||||||
≤40 | 12 | (44) | 10 | (83) | 2 | (17) | 10 | (42) | 9 | (90) | 1 | (10) | |||||
≥70 | 15 | (56) | 7 | (47) | 8 | (53) | 0.06 | 5.71(0.92–35.48) | 14 | (58) | 5 | (36) | 9 | (64) | 0.02 | 16.20(1.57–167.74) | |
Differentiation classification | |||||||||||||||||
High+Middle | 23 | (85) | 13 | (57) | 10 | (43) | 14 | (58) | 6 | (43) | 8 | (57) | |||||
Low | 4 | (15) | 4 | (100) | 0 | (0) | 0.10 | 10 | (42) | 8 | (80) | 2 | (20) | 0.08 | 0.19(0.03–1.23) | ||
Tumor stage (T) classification | |||||||||||||||||
T1+T2 | 6 | (22) | 4 | (67) | 2 | (33) | 2 | (8) | 1 | (50) | 1 | (50) | |||||
T3+T4 | 21 | (78) | 13 | (62) | 8 | (38) | 0.57 | 1.88(0.22–15.93) | 22 | (92) | 13 | (59) | 9 | (41) | 0.73 | 0.75(0.15–3.83) | |
Tumor stage (N) classification | |||||||||||||||||
N0 | 20 | (74) | 13 | (65) | 7 | (35) | 15 | (63) | 9 | (60) | 6 | (40) | |||||
N1 | 7 | (26) | 4 | (57) | 3 | (43) | 0.41 | 2.18(0.35–13.76) | 9 | (38) | 5 | (56) | 4 | (44) | 0.83 | 0.83(0.16–4.44) | |
Tumor stage (TNM) classification | |||||||||||||||||
I+II | 20 | (74) | 12 | (60) | 8 | (40) | 21 | (88) | 12 | (57) | 9 | (43) | |||||
III+IV | 7 | (26) | 5 | (71) | 2 | (29) | 0.59 | 1.67(0.26–10.79) | 3 | (13) | 2 | (67) | 1 | (33) | 0.76 | 1.50(0.12–19.24) | |